re: Ann: New Drug Application for AXIRON acce... Depends how you look at it Andrew. I got in when it was sitting sub 50 cents pretty much about this time last year. So it's all looking pretty good to me.
I guess with Biotech's you have to buy off the fundamentals - good technology, well at least one that's not relying on rocket science, a clearly defined need in a growing market and a management team who are capable of delivering what they say and that don't promise the world. (Which is of course the polar opposite to the miners.)
But if you look around the biotech sector there are some companies that I reckon would all fit the criteria above and who have all had a pretty good run over the last 12 months and will more than likely continue to move northwards. Sure ACR hasn't hit the 3.50 I reckon it will get to, but I think it's a matter of when, not if.
Add to My Watchlist
What is My Watchlist?
